Filing Flows

Filing Flows › 8-K events › Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical: completion of an acquisition or disposition of assets

Form 8-K filed Nov 3, 2026 · items 2.01, 2.02

Completion of an acquisition or disposition of assetsUltragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

What the filing says

On October 30, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) completed the previously disclosed sale (the “PRV Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the PRV by the U.S.

Read the filing on SEC EDGAR →

What usually followsAcross 2,671 8-Ks reporting Item 2.01 (completed acquisition or disposition) in our universe, the stock's median move the next session was +0.1% (typical size ±1.6%, up 52% of the time); over the following 21 sessions, +1.2%. Item 2.02: +0.2% next session across 69,115. Every item ranked →

What this kind of filing means

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Ultragenyx Pharmaceutical at a glance

Latest quarterQ3 2026
Revenue$173.0M
Revenue Y/Y+8%
Operating margin-63.6%
IndustryPharmaceutical Preparations

Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%. The chart follows the revenue to costs, profit and cash.

Ultragenyx Pharmaceutical: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent earnings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.